Dynavax Announces FDA Approval of HEPLISAV-B(TM) for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
343
Dynavax Announces FDA Approval of HEPLISAV-B(TM) for Prevention of Hepatitis B in Adults

BERKELEY, CA --(Marketwired - November 09, 2017) - Dynavax Technologies Corporation ( NASDAQ : DVAX ) today announced that the U.S. Food and Drug Administration (FDA) has approved HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. HEPLISAV-B is the first new hepatitis B vaccine in the United States in more than 25 years and the only two-dose hepatitis B vaccine for adults.

Hepatitis B is an extremely infectious and potentially deadly virus affecting a wide range of adults in the United States. There is no cure for hepatitis B, and infections are on the rise. In 2015, new cases of acute hepatitis B increased by more than 20 percent nationally.(i) Hepatitis B can be prevented through effective vaccination. Current hepatitis B vaccines require three shots over a six-month period, however, almost half of adults fail to complete the series within one year.(ii)

"Prevention of hepatitis B in adults through vaccination is more important than ever given the increase in the rate of infections," said William Schaffner, M.D., professor of Preventive Medicine, Vanderbilt University Medical Center. "Too many at-risk adults remain unprotected against this virus. A two-dose schedule with higher rates of protection, along with other strategies, may help us move closer to the goal of eliminating hepatitis B as a public health problem in the United States."

The approval of HEPLISAV-B was based on data from three Phase 3 non-inferiority trials of nearly 10,000 adult participants who received HEPLISAV-B. The pivotal studies compared HEPLISAV-B administered in two doses over one month to Engerix-B administered in three doses over a six-month schedule. Results from the largest Phase 3 trial, which included 6,665 participants, showed that HEPLISAV-B demonstrated a statistically significantly higher rate of protection of 95% compared with 81% for Engerix-B. In a subgroup analysis of 961 participants with Type 2 diabetes, HEPLISAV-B demonstrated a statistically significantly higher rate of protection of 90% compared to 65% for Engerix-B. Across the three clinical trials, the most common local reaction was injection site pain (23% to 39%). The most common systemic reactions were fatigue (11% to 17%) and headache (8% to 17%).

"HEPLISAV-B is the first FDA-approved product for Dynavax and demonstrates our ability to develop innovative products and progress them from discovery to commercialization," said Eddie Gray, chief executive officer of Dynavax. "We would like to thank the many study participants and clinical trial investigators who contributed to the development of HEPLISAV-B. We expect that it will become an essential tool in the public health community's fight to prevent hepatitis B, and we look forward to making HEPLISAV-B available to clinicians and their adult patients."

Dynavax expects to commercially launch HEPLISAV-B in the United States in the first quarter of 2018. In preparation for launch, Dynavax has been building commercial infrastructure and optimizing manufacturing processes to meet anticipated demand.

Conference Call Details The Dynavax management team will host a conference call and webcast today, Thursday, November 9, 2017 at 5:00 p.m. Eastern Time, to provide more information about the FDA approval of HEPLISAV-B. The live call can be accessed by phone by dialing (877) 479-1857 from the U.S. and Canada or +1 (503) 343-6309 internationally and using the passcode 5357789. The live call is being webcast and can be accessed in the "Investors and Media" section of the Company's website at www.dynavax.com . A replay of the webcast will be available for 30 days following the live event.

About Hepatitis B Hepatitis B is a viral disease of the liver that can become chronic and lead to cirrhosis, liver cancer and death. The hepatitis B virus is 50 to 100 times more infectious than HIV,(iii) and transmission is on the rise. There is no cure for hepatitis B, but effective vaccination can prevent the disease. In adults, hepatitis B is spread through contact with infected blood and through unprotected sex with an infected person. The CDC recommends vaccination for those at high risk for infection due to their jobs, lifestyle, living situations and travel to certain areas.(iv) Because people with diabetes are particularly vulnerable to infection, the CDC recommends vaccination for adults age 19 to 59 with diabetes as soon as possible after their diagnosis, and for people age 60 and older with diabetes at their physician's discretion.(v) Approximately 20 million U.S. adults have diabetes, and 1.5 million new cases of diabetes are diagnosed each year.(vi)

About HEPLISAV-B HEPLISAV-B is an adult hepatitis B vaccine that combines hepatitis B surface antigen with Dynavax's proprietary Toll-like Receptor (TLR) 9 agonist to enhance the immune response. Dynavax has worldwide commercial rights to HEPLISAV-B.

Indication and Use HEPLISAV-B is indicated for active immunization against infection caused by all known subtypes of hepatitis B virus. HEPLISAV-B is approved for use in adults 18 years of age and older.

Important Safety Information (ISI) Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient reported adverse reactions reported within 7 days of vaccination were injection site pain (23% to 39%), fatigue (11% to 17%) and headache (8% to 17%).

For full Prescribing Information for HEPLISAV-B, click here .

About Dynavax Dynavax is a commercial-stage biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-B, a hepatitis B vaccine for adults, is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com .

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the commercial launch and manufacturing of HEPLISAV-B. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the company will be able to build the commercial infrastructure required to launch HEPLISAV-B; whether we will launch HEPLISAV-B in the first quarter of 2018; whether we will be able to ramp up manufacturing activities to meet demand for HEPLISAV-B; whether the CDC's Advisory Committee on Immunization Practices (ACIP) will add HEPLISAV-B to its adult vaccination schedule during its February 2018 meeting, or at all; whether potential claims against us, including those based on patent rights of others, will result in an injunction against sales or otherwise impact commercialization and sales; and the results of clinical studies of Dynavax's product candidates, such as SD-101, and the impact of those results on the initiation or continuation of subsequent studies for those product candidates, and issues arising in the regulatory process; and other risks detailed in the "Risk Factors" section of our most recent current periodic report filed with the SEC. These statements represent our estimates and assumptions only as of the date of this press release. We do not undertake any obligation to update publicly any such forward-looking statements, even if new information becomes available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the SEC.

(i) CDC. https://www.cdc.gov/hepatitis/statistics/2015...m#tabs-5-8 . Fig 3.2

(ii) Nelson J, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents and adults: results from a Vaccine Safety Datalink Study. American Journal of Public Health. 2009;99:S2.

(iii) CDC. https://www.cdc.gov/hepatitis/hbv/bfaq.htm .

(iv) CDC. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm .

(v) CDC. https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf .

(vi) CDC. https://www.cdc.gov/diabetes/pdfs/data/statis...report.pdf .

Image Available: http://www.marketwire.com/library/MwGo/2017/1...a78e61.jpg
Image Available: http://www.marketwire.com/library/MwGo/2017/1...37f6cd.jpg

Embedded Video Available: https://www.youtube.com/watch?v=aDIxtQQK0Ng&feature=youtu.be

Attachment Available: http://www.marketwire.com/library/MwGo/2017/1...8cddcf.pdf

Contact: Ryan Spencer VP, Corporate Strategy & Communications 510.665.4618 rspencer@dynavax.com Media Contact: Rachel St. Martin WCG 646.894.5757 rstmartin@w2ogroup.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pompeii Fountain Tests the Value of Concrete Durability

Updated Category News Views 96

Nearly 2,000 nozzles throwing water around a public attraction is a fine way to expose every weak seam in a concrete job. The Fontana Danzante in Pompei, completed in late 2025, is not some quiet decorative basin. It is described as Italy's largest fountain, a nearly 200-meter installation near the Pompeii Archaeological Park that continuously stores, circulates and...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 65

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 45

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
SEIA's Young Advisors Put Succession Plans to the Test

Updated Category News Views 53

A $166 million average book is not a cute training-program statistic. It says SEIA’s advisors aged 30 to 39 are already carrying serious client responsibility, and that matters because the registered investment advisory business is headed into a succession crunch nobody can solve with a glossy recruiting brochure. You Cannot Hand Off Trust Like a Spare Key Clients may...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 24

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Surgery Partners Deal Faces Fresh Price Scrutiny Ahead

Updated Category News Views 35

A $23.50 cash offer can look wonderfully tidy until somebody asks how the number was built. That is where Surgery Partners shareholders find themselves after Halper Sadeh LLC said it is investigating the proposed sale of Surgery Partners, Inc. to HealthSpan Partners. The firm is examining whether the company’s board obtained a fair price, ran a conflict-free process,...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 52

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 113

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Renesas Electronics Reveals Optimistic Financial Expectations

Updated Category News Views 68

Renesas Electronics Unveils Future Financial Outlook Renesas Electronics Corporation (TSE: 6723), a leading name in the semiconductor industry, has recently shared its consolidated financial forecasts for the complete fiscal year. This announcement highlights the Group's optimistic projections for the year ending December 31, 2024, despite the inherent volatility seen in...

Continue Reading
Atos Achieves European Leadership in Mainframe Solutions Ranking

Updated Category News Views 213

Atos Secures Top Position in ISG’s Mainframes Evaluation Atos has proudly announced its recognition as a leader in ISG’s Provider Lens™ Mainframes – Services and Solutions for the fourth consecutive year. This accolade highlights Atos' extensive experience, innovative strategies, and commitment to excellence in service delivery. Leadership in Multiple Quadrants In...

Continue Reading
Custom Upholstered Furniture: Comfort Built to Last

Updated Category News Views 150

Rethinking Furniture Comfort: Not Just a Luxury Diving into the world of custom upholstered furniture with insights from Randy Marohn is like finding a cheat sheet for comfort. Seriously, it ain't just about plush cushions or slick fabrics—it's a bonafide science. Marohn, from Sans Furniture Inc. in good ol’ Hamburg, NY, unfolds a tale of intentional design and...

Continue Reading
Cyble Achieves Users' Love Badge With Outstanding Category Wins

Updated Category News Views 84

Cyble Earns G2 'Users Love Us' Badge for Winter 2026 Cyble, a leader in the field of AI-driven cybersecurity and threat intelligence, has recently achieved significant recognition in the G2 Winter 2026 Reports. This includes acquiring the esteemed 'Users Love Us' badge, along with 18 category victories within the domains of threat intelligence, digital risk protection,...

Continue Reading
SunPower Strengthens Sales Force for Future Expansion

Updated Category News Views 210

SunPower Expands Its Sales Force to Drive Future Growth Recently, SunPower Inc. (NASDAQ: SPWR) has made significant strides in expanding its sales force after successfully integrating the sales team from Sunder Energy. The merger promises to boost SunPower's operational effectiveness while setting the stage for unprecedented revenue potential. The company is poised to...

Continue Reading